3-CI-AHPC treatment of AML-bearing mice
Treatment . | Cells implanted . | Schedule . | Total dose, mg/kg . | Mean body wt loss, g per mouse . | Body wt loss, % . | Median day of tumor death (range) . | % ILS . | Log cell kill . |
|---|---|---|---|---|---|---|---|---|
| No Rx | 5 × 106 | NA | NA | +0.0 | +0.0 | 6 (6-8) | NA | NA |
| No Rx | 5 × 104 | NA | NA | +1.2 | +5.7 | 9 (9-9) | NA | NA |
| No Rx | 5 × 102 | NA | NA | +0.0 | +0.0 | 12 (12-12) | NA | NA |
| 3-CI-AHPC | 5 × 106 | qd 1-4 | 140 | −3.6 | −17.3 | 11 (10-11) | 83 | 3.3 |
| 3-CI-AHPC | 5 × 106 | qd 1-5 | 115 | −1.2 | −5.8 | 11 (10-11) | 83 | 3.3 |
| 3-CI-AHPC | 5 × 106 | qd 1-5 | 80 | +0.0 | +0.0 | 9 (8-10) | 50 | 2.0 |
Treatment . | Cells implanted . | Schedule . | Total dose, mg/kg . | Mean body wt loss, g per mouse . | Body wt loss, % . | Median day of tumor death (range) . | % ILS . | Log cell kill . |
|---|---|---|---|---|---|---|---|---|
| No Rx | 5 × 106 | NA | NA | +0.0 | +0.0 | 6 (6-8) | NA | NA |
| No Rx | 5 × 104 | NA | NA | +1.2 | +5.7 | 9 (9-9) | NA | NA |
| No Rx | 5 × 102 | NA | NA | +0.0 | +0.0 | 12 (12-12) | NA | NA |
| 3-CI-AHPC | 5 × 106 | qd 1-4 | 140 | −3.6 | −17.3 | 11 (10-11) | 83 | 3.3 |
| 3-CI-AHPC | 5 × 106 | qd 1-5 | 115 | −1.2 | −5.8 | 11 (10-11) | 83 | 3.3 |
| 3-CI-AHPC | 5 × 106 | qd 1-5 | 80 | +0.0 | +0.0 | 9 (8-10) | 50 | 2.0 |
Percentage increase in lifespan (% ILS) calculated as follows: For leukemic mice, % ILS = T - C/C × 100, in which C = the median day of death of the control group and T = the median day of death of the treated group. Rx indicates treatment; NA, not applicable; and qd, once a day.